{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-088719","form_type":"8-K","ticker":"NMTC","cik":"0001500198","company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","filed_at":"2026-08-13T12:15:26+00:00","discovered_at":"2026-08-13T12:20:03.845897+00:00","generated_at":"2026-08-13T12:20:12.414818+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NeuroOne Q3 FY2026 revenue up 16% to $2.0M; gross margin 59.9%, net loss $2.0M","bullets":["Product revenue $2.0M, +16% YoY; product gross margin 59.9% vs 53.9% (record).","New product orders $2.7M in Q3, +43% YoY; backlog $1.7M; FY2026 orders $11.2M.","Net loss $2.0M ($0.23 basic, $0.28 diluted) vs $1.5M loss prior year; cash $2.0M.","Received ISO 13485 certification; StereoCED platform expected by end FY2026 for research/IDE studies.","Lead investor raised stake from 7.4% to 12.5% post-quarter; raised $1.0M via ATM on July 13."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-088719","json":"https://secwatch.observer/filing/0001213900-26-088719.json","markdown":"https://secwatch.observer/filing/0001213900-26-088719.md","text":"https://secwatch.observer/filing/0001213900-26-088719.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1500198/000121390026088719/0001213900-26-088719-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1500198/000121390026088719/ea0301787-8k_neuroone.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T12:20:12.414818+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}